These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19546250)

  • 1. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
    Wrishko RE; Ernest CS; Small DS; Li YG; Weerakkody GJ; Riesmeyer JR; Macias WL; Rohatagi S; Salazar DE; Antman EM; Wiviott SD; Braunwald E; Ni L
    J Clin Pharmacol; 2009 Aug; 49(8):984-98. PubMed ID: 19546250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis.
    Ernest CS; Heathman MA; Wrishko RE
    J Clin Pharmacol; 2009 Aug; 49(8):973-83. PubMed ID: 19602721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy.
    Riesmeyer JS; Salazar DE; Weerakkody GJ; Ni L; Wrishko RE; Ernest CS; Luo J; Li YG; Small DS; Rohatagi S; Macias WL
    J Clin Pharmacol; 2012 Jun; 52(6):789-97. PubMed ID: 21628601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.
    Small DS; Li YG; Ernest CS; April JH; Farid NA; Payne CD; Winters KJ; Rohatagi S; Ni L
    J Clin Pharmacol; 2011 Mar; 51(3):321-32. PubMed ID: 20410452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
    Small DS; Farid NA; Payne CD; Konkoy CS; Jakubowski JA; Winters KJ; Salazar DE
    Clin Pharmacokinet; 2010 Dec; 49(12):777-98. PubMed ID: 21053990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Ernest CS; Small DS; Rohatagi S; Salazar DE; Wallentin L; Winters KJ; Wrishko RE
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):593-618. PubMed ID: 19023649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.
    Small DS; Wrishko RE; Ernest CS; Ni L; Winters KJ; Farid NA; Li YG; Brandt JT; Salazar DE; Borel AG; Kles KA; Payne CD
    J Clin Pharm Ther; 2009 Oct; 34(5):585-94. PubMed ID: 19744014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.
    Small DS; Farid NA; Li YG; Ernest CS; Winters KJ; Salazar DE; Payne CD
    J Clin Pharm Ther; 2009 Oct; 34(5):575-83. PubMed ID: 19744013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Small DS; Farid NA; Payne CD; Weerakkody GJ; Li YG; Brandt JT; Salazar DE; Winters KJ
    J Clin Pharmacol; 2008 Apr; 48(4):475-84. PubMed ID: 18303127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.
    Moser BA; LaBell ES; Chigutsa E; Jakubowski JA; Small DS
    Clin Pharmacokinet; 2018 Feb; 57(2):243-254. PubMed ID: 28578536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
    Dobesh PP
    Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
    Styles L; Heiselman D; Heath LE; Moser BA; Small DS; Jakubowski JA; Zhou C; Redding-Lallinger R; Heeney MM; Quinn CT; Rana SR; Kanter J; Winters KJ
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):1-9. PubMed ID: 25493452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.
    Farid NA; Jakubowski JA; Payne CD; Li YG; Jin Y; Ernest II CS; Winters KJ; Brandt JT; Salazar DE; Small DS
    Curr Med Res Opin; 2009 Aug; 25(8):1821-9. PubMed ID: 19530977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
    Li YG; Ni L; Brandt JT; Small DS; Payne CD; Ernest CS; Rohatagi S; Farid NA; Jakubowski JA; Winters KJ
    Platelets; 2009 Aug; 20(5):316-27. PubMed ID: 19637095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
    Alban S
    Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disposition of prasugrel, a novel thienopyridine, in humans.
    Farid NA; Smith RL; Gillespie TA; Rash TJ; Blair PE; Kurihara A; Goldberg MJ
    Drug Metab Dispos; 2007 Jul; 35(7):1096-104. PubMed ID: 17403916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prasugrel, a third generation thienopyridine and potent platelet inhibitor.
    Gurbel PA; Tantry US
    Curr Opin Investig Drugs; 2008 Mar; 9(3):324-36. PubMed ID: 18311669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
    Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
    Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Takahashi M; Kurihara A; Okazaki O; Farid NA; Ikeda T
    Xenobiotica; 2009 Mar; 39(3):218-26. PubMed ID: 19280520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.